Brief: Cidara Therapeutics Provides Update On Rezzayo™ (Rezafungin For Injection)
31/07/2023 21:31
July 31 (Reuters) - Cidara Therapeutics Inc CDTX.O :
* CIDARA THERAPEUTICS PROVIDES UPDATE ON REZZAYO™
(REZAFUNGIN FOR
INJECTION)
* CIDARA THERAPEUTICS INC - EMA REGULATORY DECISION FOR
REZAFUNGIN
EXPECTED BY YEAR END 2023
* CIDARA THERAPEUTICS INC - CIDARA'S U.S. COMMERCIAL
PARTNER,
MELINTA THERAPEUTICS, HAS INITIATED COMMERCIAL LAUNCH OF REZZAYO
* CIDARA THERAPEUTICS - RETAINS RIGHTS TO REZAFUNGIN IN
JAPAN, IS
CURRENTLY EVALUATING POTENTIAL COMMERCIAL PARTNERSHIP
OPPORTUNITIES IN JAPAN
Source text for Eikon: ID:nGNX2JtrD7
Further company coverage: CDTX.O
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade